drugset / Trial / NCT01517880

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy

NCT01517880 ↗

Phase 2 Completed 46 enrolled Ultragenyx Pharmaceutical Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

GNE myopathy or hereditary inclusion body myopathy (HIBM) is a severe progressive metabolic myopathy caused by a defect in the biosynthetic pathway for sialic acid (SA).

Timeline

Start
2012-05
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Sialic Acid Extended Release Unknown 3000 mg —
Subject Sialic Acid Extended Release Unknown 6000 mg —